MYGN - Myriad Genetics Inc Stock Price, Fair Value and News

19.16USD-0.39 (-1.99%)Market Closed

Market Summary

USD19.16-0.39

Market Closed

-1.99%

MYGN Stock Price

View Fullscreen

MYGN RSI Chart

MYGN Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-6.54

Price/Sales (Trailing)

2.29

EV/EBITDA

-8.25

Price/Free Cashflow

-15.53

MYGN Price/Sales (Trailing)

MYGN Profitability

Operating Margin

80.57%

EBT Margin

-34.81%

Return on Equity

-33.62%

Return on Assets

-22.97%

Free Cashflow Yield

-6.44%

MYGN Fundamentals

MYGN Revenue

Revenue (TTM)

753.2M

Rev. Growth (Yr)

10.57%

Rev. Growth (Qtr)

2.45%

MYGN Earnings

Earnings (TTM)

-263.3M

Earnings Growth (Yr)

26.24%

Earnings Growth (Qtr)

49.1%

Breaking Down MYGN Revenue

Last 7 days

-5.8%

Last 30 days

-9.4%

Last 90 days

-6.8%

Trailing 12 Months

-14.0%

How does MYGN drawdown profile look like?

MYGN Financial Health

Current Ratio

2.01

Debt/Equity

0.05

Debt/Cashflow

-2.88

MYGN Investor Care

Shares Dilution (1Y)

10.65%

Diluted EPS (TTM)

-3.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	694.7M	698.9M	734.4M	753.2M
2022	682.4M	672.3M	661.4M	678.4M
2021	566.1M	662.3M	684.4M	690.6M
2020	760.8M	638.6M	597.5M	557.0M
2019	829.6M	851.1M	835.1M	813.4M
2018	749.4M	743.7M	767.2M	796.1M
2017	743.5M	769.9M	769.8M	761.0M
2016	756.6M	740.5M	735.9M	739.3M
2015	721.9M	722.5M	737.2M	746.1M
2014	763.6M	778.2M	744.5M	724.9M
2013	572.0M	613.2M	682.2M	737.1M
2012	470.5M	496.0M	519.0M	545.3M
2011	388.6M	402.1M	420.7M	443.0M
2010	353.6M	362.6M	369.4M	377.1M
2009	0	326.5M	335.6M	344.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Myriad Genetics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 14, 2024	verratti mark	sold (taxes)	-21,035	19.55	-1,076	chief commercial officer
Apr 14, 2024	muzzey dale	sold (taxes)	-18,377	19.55	-940	chief scientific officer
Apr 06, 2024	munk natalie	sold (taxes)	-11,771	20.26	-581	chief accounting officer
Mar 25, 2024	munk natalie	sold (taxes)	-7,978	21.98	-363	chief accounting officer
Mar 24, 2024	diaz paul j	sold (taxes)	-1,019,080	22.24	-45,822	president and ceo
Mar 24, 2024	haas kevin richard	sold (taxes)	-64,273	22.24	-2,890	chief technology officer
Mar 24, 2024	muzzey dale	sold (taxes)	-20,972	22.24	-943	chief scientific officer
Mar 24, 2024	verratti mark	sold (taxes)	-72,168	22.24	-3,245	chief commercial officer
Mar 24, 2024	munk natalie	sold (taxes)	-21,817	22.24	-981	chief accounting officer
Mar 22, 2024	diaz paul j	sold (taxes)	-449,292	22.24	-20,202	president and ceo

Which funds bought or sold MYGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-230	-	-%
Apr 11, 2024	Clarus Wealth Advisors	sold off	-100	-204,404	-	-%
Apr 08, 2024	TOMPKINS FINANCIAL CORP	unchanged	-	1,831	17,909	-%
Apr 05, 2024	CWM, LLC	added	0.58	4,000	30,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	0.66	86.00	25,968	-%
Apr 03, 2024	Versant Capital Management, Inc	unchanged	-	2,208	21,597	0.01%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-11.89	5,246	107,356	-%
Mar 11, 2024	VANGUARD GROUP INC	added	8.61	43,521,600	190,524,000	-%
Mar 05, 2024	Fisher Asset Management, LLC	added	10.73	735,323	3,023,520	-%
Mar 04, 2024	TUCKER ASSET MANAGEMENT LLC	new	-	230	230	-%

Are Funds Buying or Selling MYGN?

Are funds buying MYGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MYGN

No. of Funds

Unveiling Myriad Genetics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	millennium management llc	4.7%	4,262,021	SC 13G
Feb 14, 2024	camber capital management lp	8.5%	2,013	SC 13G/A
Feb 14, 2024	glenview capital management, llc	5.97%	5,283,982	SC 13G/A
Feb 13, 2024	vanguard group inc	11.12%	9,954,233	SC 13G/A
Feb 08, 2024	wellington management group llp	8.07%	7,219,706	SC 13G/A
Jan 24, 2024	state street corp	5.25%	4,700,631	SC 13G/A
Jan 23, 2024	integrated core strategies (us) llc	4.0%	3,559,497	SC 13G/A
Jan 22, 2024	blackrock inc.	16.6%	14,658,349	SC 13G/A
Oct 17, 2023	integrated core strategies (us) llc	5.1%	4,164,600	SC 13G
Mar 01, 2023	glenview capital management, llc	5.31%	4,312,131	SC 13G

Recent SEC filings of Myriad Genetics Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 10, 2024	144	Notice of Insider Sale Intent
Apr 08, 2024	4	Insider Trading
Mar 28, 2024	4/A	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to Myriad Genetics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	177.3B	23.9B	-3.91%	-4.78%	37.37	7.42	-10.33%	-33.23%
A	41.1B	6.7B	-4.92%	0.73%	33.25	6.1	-2.81%	-6.58%
IDXX	40.8B	3.7B	-7.22%	1.87%	48.33	11.16	8.72%	24.44%
DGX	14.2B	9.3B	0.30%	-9.60%	16.68	1.54	-6.38%	-9.73%
CRL	12.1B	4.1B	-8.95%	15.76%	25.51	2.93	3.86%	-2.39%
MEDP	11.9B	1.9B	-2.43%	101.48%	42.11	6.31	29.17%	15.26%
EXAS	11.9B	2.5B	13.24%	-2.16%	-58.11	4.75	19.93%	67.26%
NTRA	10.9B	1.1B	0.99%	75.89%	-25.11	10.08	31.99%	20.63%
MID-CAP
NEOG	2.6B	929.2M	-20.88%	-25.40%	1.7K	2.8	28.93%	111.61%
GH	2.1B	563.9M	-3.78%	-30.33%	-4.33	3.68	25.45%	26.76%
SMALL-CAP
CDNA	425.1M	280.3M	-19.03%	-7.55%	-2.23	1.52	-12.89%	-148.37%
ACRS	86.5M	31.2M	4.27%	-86.20%	-0.98	2.77	5.03%	-1.81%
AWH	41.5M	9.2M	-6.67%	-36.96%	-2.48	4.53	11.85%	44.12%
APDN	6.1M	9.0M	-2.70%	-65.71%	-0.85	0.68	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Myriad Genetics Inc News

Latest updates

Myriad Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.4%	196,600,000	191,900,000	183,500,000	181,200,000	177,800,000	156,400,000	179,300,000	164,900,000	160,800,000	167,300,000	189,400,000	173,100,000	154,600,000	145,200,000	93,200,000	164,000,000	195,100,000	186,300,000	215,400,000	216,600,000	216,800,000
Costs and Expenses	-9.5%	228,000,000	252,000,000	297,200,000	233,400,000	230,000,000	201,400,000	197,100,000	190,500,000	203,900,000	247,200,000	210,200,000	219,800,000	202,800,000	184,800,000	161,500,000	297,700,000	203,900,000	207,200,000	221,000,000	210,700,000	210,700,000
S&GA Expenses	6.1%	144,400,000	136,100,000	140,700,000	151,700,000	146,500,000	130,500,000	127,100,000	110,600,000	75,600,000	180,600,000	135,200,000	146,400,000	132,800,000	124,100,000	107,400,000	132,900,000	134,300,000	135,500,000	149,800,000	140,600,000	135,200,000
R&D Expenses	-12.5%	21,000,000	24,000,000	21,200,000	22,500,000	23,400,000	20,500,000	20,300,000	21,200,000	20,500,000	18,800,000	19,500,000	23,100,000	18,200,000	17,600,000	17,400,000	19,700,000	18,800,000	21,300,000	20,900,000	21,500,000	22,400,000
EBITDA Margin	12.0%	-0.26	-0.30	-0.29	-0.15	-0.12	-0.12	0.01	0.04	0.02	0.02	-0.10	-0.21	-	-	-	-	-	-	-	-	-
Interest Expenses	-10.0%	900,000	1,000,000	500,000	500,000	900,000	800,000	600,000	900,000	500,000	1,100,000	2,000,000	3,000,000	2,900,000	2,900,000	3,100,000	2,300,000	2,500,000	2,900,000	3,200,000	3,200,000	3,400,000
Income Taxes	-1200.0%	-1,100,000	100,000	-	2,100,000	-9,800,000	-9,100,000	-3,800,000	-5,900,000	-35,900,000	15,200,000	900,000	-10,100,000	-12,500,000	-28,500,000	-3,000,000	-15,900,000	-3,100,000	-1,700,000	-3,400,000	-3,600,000	1,000,000
Earnings Before Taxes	47.2%	-32,300,000	-61,200,000	-116,100,000	-52,600,000	-52,100,000	-44,200,000	-17,900,000	-26,400,000	-43,500,000	39,800,000	-3,800,000	-49,600,000	-50,400,000	-43,700,000	-58,500,000	-131,100,000	-11,400,000	-22,300,000	-7,700,000	3,300,000	3,600,000
EBT Margin	9.3%	-0.35	-0.38	-0.38	-0.24	-0.21	-0.20	-0.07	-0.05	-0.08	-0.09	-0.22	-0.36	-	-	-	-	-	-	-	-	-
Net Income	49.1%	-31,200,000	-61,300,000	-116,100,000	-54,700,000	-42,300,000	-35,100,000	-14,100,000	-20,500,000	-7,600,000	24,600,000	-4,700,000	-39,500,000	-37,900,000	-15,200,000	-55,400,000	-115,200,000	-8,300,000	-20,600,000	-4,200,000	6,900,000	2,600,000
Net Income Margin	6.4%	-0.35	-0.37	-0.36	-0.21	-0.17	-0.12	-0.03	-0.01	-0.04	-0.08	-0.15	-0.26	-	-	-	-	-	-	-	-	-
Free Cashflow	-147.5%	-54,700,000	-22,100,000	-900,000	-33,200,000	-7,300,000	-2,800,000	-49,700,000	-46,500,000	-9,500,000	-39,300,000	-4,400,000	71,800,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.2%	1,147	1,149	1,187	1,169	1,199	1,212	1,210	1,255	1,321	1,336	1,360	1,337	1,419	1,445	1,405	1,447	1,578	1,591	1,563	1,557	1,557
Current Assets	18.2%	314	265	294	262	275	352	367	427	485	499	539	329	389	395	332	355	365	330	349	343	337
Cash Equivalents	73.8%	132	76.00	103	54.00	57.00	109	104	164	257	295	118	149	117	118	164	121	81.00	90.00	93.00	85.00	91.00
Inventory	-12.4%	22.00	25.00	23.00	22.00	20.00	20.00	15.00	16.00	15.00	19.00	18.00	25.00	27.00	27.00	29.00	31.00	28.00	28.00	31.00	32.00	33.00
Net PPE	-1.4%	119	121	112	96.00	83.00	68.00	53.00	46.00	44.00	43.00	43.00	45.00	41.00	37.00	37.00	37.00	37.00	55.00	57.00	59.00	59.00
Goodwill	0.3%	287	287	287	287	287	237	238	239	239	240	240	328	329	328	328	327	408	416	417	416	413
Liabilities	-22.0%	363	466	452	334	313	295	263	305	353	367	458	462	538	535	486	480	501	517	474	476	493
Current Liabilities	-25.5%	156	209	221	143	137	129	120	166	204	203	271	149	146	134	147	113	112	115	118	109	113
Long Term Debt	0%	39.00	39.00	38.00	-	-	-	-	-	-	-	-	154	225	225	224	225	225	225	234	263	273
LT Debt, Non Current	0%	39.00	39.00	38.00	-	-	-	-	-	-	-	-	-	225	-	-	-	-	-	-	-	-
Shareholder's Equity	14.6%	783	683	735	835	886	917	947	950	968	969	902	875	881	909	918	967	1,077	1,075	1,089	1,082	1,064
Retained Earnings	-5.2%	-629	-598	-537	-420	-366	-323	-288	-274	-254	-246	-271	-266	-227	-189	-173	-118	-3.30	5.00	26.00	30.00	23.00
Additional Paid-In Capital	10.1%	1,416	1,286	1,277	1,263	1,260	1,251	1,244	1,232	1,226	1,219	1,177	1,145	1,110	1,101	1,097	1,093	1,085	1,076	1,068	1,057	1,046
Shares Outstanding	9.5%	90.00	82.00	82.00	82.00	81.00	81.00	81.00	80.00	80.00	80.00	78.00	77.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-0.10	-0.10	-	-	-	-	-	0.00	-	-	-0.10	-0.10
Float	-	-	-	1,898	-	-	-	1,465	-	-	-	2,377	-	-	-	847	-	2,030	-	-	-	2,130

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-147.5%	-54,700	-22,100	-900	-33,200	-7,300	-2,800	-49,700	-46,500	-9,500	-39,300	-4,400	71,800	-14,400	-59,300	30,000	16,800	-1,900	15,800	31,500	6,600	37,800
Share Based Compensation	-10.3%	10,400	11,600	11,200	7,500	8,200	9,400	10,400	10,100	8,400	10,000	8,900	9,000	6,500	8,400	1,900	7,500	7,000	8,800	8,800	9,500	7,500
Cashflow From Investing	-380.0%	-12,000	-2,500	11,800	34,600	-35,600	11,400	-12,000	-41,300	-25,900	291,000	1,100	8,200	10,900	17,100	10,350	23,200	-7,200	-7,100	4,500	-3,800	-8,100
Cashflow From Financing	4976.0%	121,900	-2,500	38,400	-4,900	-2,100	-3,600	2,500	-4,800	-1,100	-74,500	-26,500	-48,500	1,800	-3,900	950	200	1,100	-12,300	-27,800	-9,400	-32,600
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	46,150	-50,000

MYGN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 753.2	$ 678.4	$ 690.6
Costs and expenses:
Research and development expense	88.7	85.4	81.9
Selling, general, and administrative expense	572.9	514.7	537.8
Legal settlements	112.8	0.0	62.0
Goodwill and long-lived asset impairment charges	0.0	16.9	1.8
Total costs and expenses	1,010.6	819.0	881.1
Operating loss	(257.4)	(140.6)	(190.5)
Other income (expense):
Interest income	2.5	2.6	0.7
Interest expense	(2.9)	(3.2)	(6.6)
Other	(4.4)	0.6	139.3
Total other income (expense)	(4.8)	0.0	133.4
Loss before income tax	(262.2)	(140.6)	(57.1)
Income tax expense (benefit)	1.1	(28.6)	(29.9)
Net loss	$ (263.3)	$ (112.0)	$ (27.2)
Net loss per share:
Basic (in dollars per share)	$ (3.18)	$ (1.39)	$ (0.35)
Diluted (in dollars per share)	$ (3.18)	$ (1.39)	$ (0.35)
Weighted average shares outstanding:
Basic (in shares)	82.8	80.6	78.0
Diluted (in shares)	82.8	80.6	78.0
Testing Revenue
Total revenue	$ 753.2	$ 678.4	$ 666.4
Costs and expenses:
Costs and expenses	236.2	202.0	185.7
Other revenue
Total revenue	0.0	0.0	24.2
Costs and expenses:
Costs and expenses	$ 0.0	$ 0.0	$ 11.9

MYGN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 132.1	$ 56.9
Marketable investment securities	8.8	58.0
Trade accounts receivable	114.3	101.6
Inventory	22.0	20.1
Prepaid taxes	17.0	17.6
Prepaid expenses and other current assets	19.4	20.4
Total current assets	313.6	274.6
Operating lease right-of-use assets	61.6	103.9
Long-term marketable investment securities	0.0	54.8
Property, plant and equipment, net	119.0	83.4
Intangibles, net	349.5	379.7
Goodwill	287.4	286.8
Other assets	15.4	15.5
Total assets	1,146.5	1,198.7
Current liabilities:
Accounts payable	25.8	28.8
Accrued liabilities	113.9	94.3
Current maturities of operating lease liabilities	16.2	14.1
Total current liabilities	155.9	137.2
Unrecognized tax benefits	30.2	26.8
Long-term debt	38.5	0.0
Noncurrent operating lease liabilities	97.4	130.9
Other long-term liabilities	41.3	18.0
Total liabilities	363.3	312.9
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 89.9 and 81.2 shares outstanding at December 31, 2023 and 2022, respectively	0.9	0.8
Additional paid-in capital	1,415.5	1,260.1
Accumulated other comprehensive loss	(3.7)	(8.9)
Accumulated deficit	(629.5)	(366.2)
Total stockholders' equity	783.2	885.8
Total liabilities and stockholders’ equity	$ 1,146.5	$ 1,198.7

About Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

CEO	Mr. Paul J. Diaz
WEBSITE	https://myriad.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	2600

Myriad Genetics Inc Frequently Asked Questions

What is the ticker symbol for Myriad Genetics Inc? What does MYGN stand for in stocks?

MYGN is the stock ticker symbol of Myriad Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Myriad Genetics Inc (MYGN)?

As of Mon Apr 15 2024, market cap of Myriad Genetics Inc is 1.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYGN stock?

You can check MYGN's fair value in chart for subscribers.

What is the fair value of MYGN stock?

You can check MYGN's fair value in chart for subscribers. The fair value of Myriad Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Myriad Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MYGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Myriad Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether MYGN is over valued or under valued. Whether Myriad Genetics Inc is cheap or expensive depends on the assumptions which impact Myriad Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYGN.

What is Myriad Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, MYGN's PE ratio (Price to Earnings) is -6.54 and Price to Sales (PS) ratio is 2.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Myriad Genetics Inc's stock?

In the past 10 years, Myriad Genetics Inc has provided -0.066 (multiply by 100 for percentage) rate of return.